Research and Clinical Trials

Neoadjuvant Chemo Prior to Radical Prostatectomy vs. Immediate Prostatectom
Brief Description  
The purpose of this study is to determine whether treatment with neoadjuvant docetaxel and androgen deprivation therapy prior to radical prostatectomy will increase the rate of 3 year biochemical progression-free survival compared to treatment with immediate radical prostatectomy alone for high-risk prostate cancer patients.
Who may be Eligible  
-Histologic documentation of prostatic adenocarcinoma -Patients with small cell, neuroendocrine or transitional cell carcinomas are not eligible -No evidence of metastatic disease on cross sectional imaging and bone scan -Must have Kattan nomogram predicted probability of being disease free 5 years after surgery of less than 60% OR Gleason sum equal to or greater than 8 -No prior treatment for prostatic adenocarcinoma including prior surgery, radiation or chemotherapy (excluding TURP) -18 years of age or older
IRB Number  
Principal Investigator  
Mahoney, John

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203